PMID- 34500492
OWN - NLM
STAT- MEDLINE
DCOM- 20211222
LR  - 20211222
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 195
IP  - 3
DP  - 2021 Nov
TI  - The impact of bridging therapy prior to CD19-directed chimeric antigen receptor 
      T-cell therapy in patients with large B-cell lymphoma.
PG  - 405-412
LID - 10.1111/bjh.17738 [doi]
AB  - In the relapsed/refractory setting for treatment of large B-cell lymphoma (LBCL), 
      chimeric antigen receptor T-cell (CAR-T) therapy has emerged as an effective 
      treatment modality. Patients often have aggressive disease that requires prompt 
      treatment in the form of bridging therapy (BT) for disease stabilisation while 
      CAR-T cells are manufactured. Patients (n = 75) undergoing CAR-T therapy infusion 
      for LBCL at our institution were identified. A total of 52 (69.3%) received BT 
      and 23 (30.7%) received no BT (NBT). BT modalities included systemic BT (SBT) in 
      28 patients, radiation BT (RBT) in 14, and high-dose steroid BT (HDS) in 10. 
      There was no difference in incidence of cytokine release syndrome or immune 
      effector cell-associated neurotoxicity syndrome between BT and NBT (P = 0.18 and 
      P = 0.53 respectively). Prolonged cytopenias at Day 180 were more common in BT 
      than NBT (50% vs. 13.3%, P = 0.04). The SBT and RBT subgroups had more cytopenias 
      at Day 180 compared to the HDS and NBT subgroups (58.3% and 57.1% vs. 20% and 
      13.3% respectively, P = 0.04). Disease response at last follow-up, 
      progression-free survival and overall survival were similar between BT, NBT, and 
      BT subgroups. In summary, BT can be safely considered in patients undergoing 
      CAR-T therapy. However, those undergoing BT with SBT or RBT are at higher risk of 
      prolonged cytopenias after CAR-T therapy.
CI  - (c) 2021 British Society for Haematology and John Wiley & Sons Ltd.
FAU - Lutfi, Forat
AU  - Lutfi F
AUID- ORCID: 0000-0002-9699-3080
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Holtzman, Noa G
AU  - Holtzman NG
AUID- ORCID: 0000-0002-5706-1109
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
AD  - Immune Deficiency Cellular Therapy Program, National Institutes of Health, 
      Bethesda, Maryland, USA.
FAU - Kansagra, Ankit J
AU  - Kansagra AJ
AD  - UT Southwestern Simmons Cancer Center, Dallas, Texas, USA.
FAU - Mustafa Ali, Moaath
AU  - Mustafa Ali M
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Bukhari, Ali
AU  - Bukhari A
AUID- ORCID: 0000-0002-5326-2261
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Yan, Jingsheng
AU  - Yan J
AD  - UT Southwestern Simmons Cancer Center, Dallas, Texas, USA.
FAU - Samanta, Santanu
AU  - Samanta S
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Gottlieb, David
AU  - Gottlieb D
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Kim, Dong W
AU  - Kim DW
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Matsumoto, Lisa R
AU  - Matsumoto LR
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Gahres, Natalie
AU  - Gahres N
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Ruehle, Kathleen
AU  - Ruehle K
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Lee, Seung T
AU  - Lee ST
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Law, Jennie Y
AU  - Law JY
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Kocoglu, Mehmet H
AU  - Kocoglu MH
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Atanackovic, Djordje
AU  - Atanackovic D
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Yared, Jean A
AU  - Yared JA
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Hardy, Nancy M
AU  - Hardy NM
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Molitoris, Jason
AU  - Molitoris J
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Mohindra, Pranshu
AU  - Mohindra P
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Rapoport, Aaron P
AU  - Rapoport AP
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
FAU - Dahiya, Saurabh
AU  - Dahiya S
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, Maryland, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20210909
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Antigens, CD19)
RN  - 0 (Biological Products)
RN  - 0 (CD19 molecule, human)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - FA2DM6879K (Vidarabine)
RN  - P2K93U8740 (fludarabine)
RN  - Q6C9WHR03O (tisagenlecleucel)
RN  - U2I8T43Y7R (axicabtagene ciloleucel)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adult
MH  - Aged
MH  - Antigens, CD19/*immunology
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biological Products/*therapeutic use
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/administration & dosage
MH  - Cytokine Release Syndrome/etiology
MH  - Female
MH  - Humans
MH  - *Immunotherapy, Adoptive/adverse effects
MH  - Kaplan-Meier Estimate
MH  - Leukapheresis
MH  - Lymphocyte Depletion
MH  - Lymphoma, Large B-Cell, Diffuse/drug therapy/etiology/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Pancytopenia/chemically induced
MH  - Progression-Free Survival
MH  - Receptors, Antigen, T-Cell/*therapeutic use
MH  - Retrospective Studies
MH  - Salvage Therapy
MH  - Vidarabine/administration & dosage/analogs & derivatives
OTO - NOTNLM
OT  - CAR-T therapy
OT  - adoptive cellular therapies
OT  - bridging therapy
OT  - cytokine release syndrome
OT  - immune effector cell-associated neurotoxicity
EDAT- 2021/09/10 06:00
MHDA- 2021/12/24 06:00
CRDT- 2021/09/09 20:31
PHST- 2021/07/08 00:00 [revised]
PHST- 2021/04/26 00:00 [received]
PHST- 2021/07/09 00:00 [accepted]
PHST- 2021/09/10 06:00 [pubmed]
PHST- 2021/12/24 06:00 [medline]
PHST- 2021/09/09 20:31 [entrez]
AID - 10.1111/bjh.17738 [doi]
PST - ppublish
SO  - Br J Haematol. 2021 Nov;195(3):405-412. doi: 10.1111/bjh.17738. Epub 2021 Sep 9.